Hazard ratio | (95% CI) | p value | |
---|---|---|---|
Age | 1.01 | 1.00–1.01 | 0.168 |
Year of diagnosis | 0.98 | 0.95–1.02 | 0.352 |
Clinical nodal stage | |||
N0 | 1 (ref) | ||
N1 | 1.15 | 0.78–1.68 | 0.468 |
N2 | 1.23 | 0.74–2.07 | 0.414 |
N3 | 1.32 | 0.88–1.99 | 0.174 |
Surgery | |||
No | 1 (ref) | ||
Yes | 0.56 | 0.42–0.74 | < 0.001 |
Chemotherapy | |||
Yes | 1 (ref) | ||
No | 1.62 | 1.24–2.14 | < 0.001 |
Targeted therapy | |||
Yes | 1 (ref) | ||
No | 2.76 | 1.70–3.05 | < 0.001 |
Antihormonal therapy | |||
Yes | 1 (ref) | ||
No | 2.16 | 1.62–2.89 | < 0.001 |
Radiation therapy | |||
Yes | 1 (ref) | ||
No | 1.11 | 0.84–1.46 | 0.457 |
Molecular subtype | |||
HR+/HER2− | 1 (Ref) | ||
HR+/HER2+ | 1.17 | 0.86–1.61 | 0.319 |
HR−/HER2+ | 1.59 | 1.12–2.24 | 0.009 |
HR−/HER2− | 1.94 | 1.41–2.67 | < 0.001 |
Location of metastases | |||
Bone only | 1 (ref) | ||
Liver only | 0.86 | 0.56–1.33 | 0.507 |
Lung only | 1.27 | 0.81–1.99 | 0.292 |
Other | 0.99 | 0.69–1.40 | 0.934 |
Multiple organs | 1.32 | 1.04–1.68 | 0.021 |